ES2530462T3 - Combinación terapia antitumoral - Google Patents
Combinación terapia antitumoral Download PDFInfo
- Publication number
- ES2530462T3 ES2530462T3 ES09751682T ES09751682T ES2530462T3 ES 2530462 T3 ES2530462 T3 ES 2530462T3 ES 09751682 T ES09751682 T ES 09751682T ES 09751682 T ES09751682 T ES 09751682T ES 2530462 T3 ES2530462 T3 ES 2530462T3
- Authority
- ES
- Spain
- Prior art keywords
- antitumor therapy
- combination antitumor
- antimetabolite
- combination
- alkylating agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un agente alquilante antimetabolito y un mimético SOD selectivo para uso en un método para tratar el cáncer, en el que el agente alquilante antimetabolito es gemcitadina o sal derivada y el mimético SOD corresponde a la Fórmula (KM4419):
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5541808P | 2008-05-22 | 2008-05-22 | |
PCT/US2009/045029 WO2009143454A2 (en) | 2008-05-22 | 2009-05-22 | Combination antitumor therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2530462T3 true ES2530462T3 (es) | 2015-03-03 |
Family
ID=41340927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES09751682T Active ES2530462T3 (es) | 2008-05-22 | 2009-05-22 | Combinación terapia antitumoral |
Country Status (6)
Country | Link |
---|---|
US (1) | US9198893B2 (es) |
EP (2) | EP2296645B1 (es) |
CA (1) | CA2724550C (es) |
ES (1) | ES2530462T3 (es) |
HK (1) | HK1155644A1 (es) |
WO (1) | WO2009143454A2 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE044234T2 (hu) | 2006-10-12 | 2019-10-28 | Galera Labs Llc | Eljárások szájnyálkahártya-gyulladás kezelésére |
WO2013048965A1 (en) * | 2011-09-26 | 2013-04-04 | Galera Therapeutics, Llc | Methods for treatment of diseases |
US9446064B2 (en) | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | Combination therapy for treating cancer |
JP2017527547A (ja) * | 2014-08-13 | 2017-09-21 | エピザイム,インコーポレイティド | 癌を処置するための併用療法 |
JP2017532312A (ja) * | 2014-09-17 | 2017-11-02 | エピザイム,インコーポレイティド | 癌を治療するための併用療法 |
CA2994845A1 (en) | 2015-08-11 | 2017-02-16 | Galera Labs, Llc | Pentaaza macrocyclic ring complexes possessing oral bioavailability |
EA201892510A3 (ru) * | 2016-05-03 | 2019-09-30 | ГАЛЕРА ЛЭБЗ, ЭлЭлСи | Комбинированная терапия для лечения рака |
CA3035766A1 (en) * | 2016-09-01 | 2018-03-08 | Galera Labs, Llc | Combination cancer therapy with pentaaza macrocyclic ring complex and ascorbate compound |
WO2018152353A2 (en) | 2017-02-15 | 2018-08-23 | Galera Labs, Llc | Pentaaza macrocyclic ring complexes for local intestinal delivery |
CN110769837A (zh) * | 2017-04-13 | 2020-02-07 | 加莱拉实验室有限责任公司 | 与五氮杂大环状环配合物的联合癌症免疫疗法 |
IL295620B2 (en) * | 2017-04-13 | 2024-01-01 | Galera Labs Llc | Cancer immunotherapy combined with a macrocyclic ring pentase complex |
EP3388082A1 (en) * | 2017-04-13 | 2018-10-17 | Galera Labs, LLC | Combination cancer immunotherapy with pentaaza macrocyclic ring complex |
JP2019131508A (ja) * | 2018-01-31 | 2019-08-08 | ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーGalera Labs, Llc | ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法 |
CN111902147A (zh) * | 2018-01-31 | 2020-11-06 | 加莱拉实验室有限责任公司 | 五氮杂大环状环配合物和基于铂的抗癌剂的组合癌症治疗 |
WO2021247009A1 (en) * | 2020-06-02 | 2021-12-09 | Galera Labs, Llc | Combination cancer therapy with pentaaza macrocyclic ring complex and hormone therapy agent |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0184365B1 (en) | 1984-12-04 | 1993-08-04 | Eli Lilly And Company | Improvements in the treatment of tumors in mammals |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
TW197439B (es) | 1991-04-04 | 1993-01-01 | Ueno Pharmaceutics Applic Res Co Ltd | |
CA2072934C (en) | 1991-07-19 | 2007-08-28 | Karl William Aston | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
US5283253A (en) | 1991-09-23 | 1994-02-01 | Florida State University | Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them |
AU3140093A (en) | 1991-11-22 | 1993-06-15 | University Of Mississippi, The | Synthesis and optical resolution of the taxol side chain and related compounds |
US5200534A (en) | 1992-03-13 | 1993-04-06 | University Of Florida | Process for the preparation of taxol and 10-deacetyltaxol |
US5440056A (en) | 1992-04-17 | 1995-08-08 | Abbott Laboratories | 9-deoxotaxane compounds |
AU4242993A (en) | 1992-05-21 | 1993-12-13 | Penn State Research Foundation, The | Cultured (taxus) tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds |
US5274137A (en) | 1992-06-23 | 1993-12-28 | Nicolaou K C | Intermediates for preparation of taxols |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US5294637A (en) | 1992-07-01 | 1994-03-15 | Bristol-Myers Squibb Company | Fluoro taxols |
US5202448A (en) | 1992-08-14 | 1993-04-13 | Napro Biotherapeutics, Inc. | Processes of converting taxanes into baccatin III |
CA2100808A1 (en) | 1992-10-01 | 1994-04-02 | Vittorio Farina | Deoxy paclitaxels |
FR2696461B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent. |
FR2696464B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III. |
FR2696462B1 (fr) | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Procédé d'obtention de la désacétyl-10 baccatine III. |
FR2696458B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Procédé de préparation de dérivés du taxane. |
FR2696463B1 (fr) | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Procédé d'obtention de la désacétyl-10 baccatine III. |
US5279949A (en) | 1992-12-07 | 1994-01-18 | Board Of Trustees Operating Michigan State University | Process for the isolation and purification of taxol and taxanes from Taxus spp |
US6204259B1 (en) | 1993-01-14 | 2001-03-20 | Monsanto Company | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
US5824701A (en) | 1993-10-20 | 1998-10-20 | Enzon, Inc. | Taxane-based prodrugs |
US5415869A (en) | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
US6245758B1 (en) | 1994-05-13 | 2001-06-12 | Michael K. Stern | Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor |
US6525041B1 (en) | 1995-06-06 | 2003-02-25 | Pharmacia Corporation | Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide |
NZ315505A (en) | 1995-08-17 | 2000-01-28 | Monsanto Co | Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands |
WO1998008833A1 (en) | 1996-08-26 | 1998-03-05 | Bristol-Myers Squibb Company | Sulfenamide taxane derivatives |
CA2264227A1 (en) | 1996-09-27 | 1998-04-02 | Raymond A. Firestone | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
AU4966597A (en) | 1996-11-19 | 1998-06-10 | Daiichi Pharmaceutical Co., Ltd. | Taxol derivatives |
US5977386A (en) | 1996-12-24 | 1999-11-02 | Bristol-Myers Squibb Company | 6-thio-substituted paclitaxels |
IL133585A0 (en) | 1997-06-20 | 2001-04-30 | Baker Norton Pharma | Soluble prodrugs of paclitaxel |
US6180620B1 (en) | 1997-06-20 | 2001-01-30 | G.D. Searle & Co. | Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals |
US6214817B1 (en) | 1997-06-20 | 2001-04-10 | Monsanto Company | Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity |
US7288665B1 (en) | 1997-08-18 | 2007-10-30 | Florida State University | Process for selective derivatization of taxanes |
JPH1192468A (ja) | 1997-09-17 | 1999-04-06 | Yakult Honsha Co Ltd | 新規なタキサン誘導体 |
JP4153660B2 (ja) | 1997-10-08 | 2008-09-24 | 株式会社横浜国際バイオ研究所 | タキソイド誘導体およびその製造方法 |
FR2863892B1 (fr) * | 2003-12-18 | 2007-05-11 | Univ Paris Descartes | Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux |
HUE044234T2 (hu) * | 2006-10-12 | 2019-10-28 | Galera Labs Llc | Eljárások szájnyálkahártya-gyulladás kezelésére |
-
2009
- 2009-05-22 WO PCT/US2009/045029 patent/WO2009143454A2/en active Application Filing
- 2009-05-22 EP EP09751682.7A patent/EP2296645B1/en active Active
- 2009-05-22 CA CA2724550A patent/CA2724550C/en active Active
- 2009-05-22 EP EP14192420.9A patent/EP2859916B1/en active Active
- 2009-05-22 ES ES09751682T patent/ES2530462T3/es active Active
- 2009-05-22 US US12/993,140 patent/US9198893B2/en active Active
-
2011
- 2011-09-19 HK HK11109854.3A patent/HK1155644A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
US20110136756A1 (en) | 2011-06-09 |
HK1155644A1 (en) | 2012-05-25 |
EP2859916A2 (en) | 2015-04-15 |
EP2296645B1 (en) | 2014-11-19 |
CA2724550A1 (en) | 2009-11-26 |
EP2859916B1 (en) | 2017-11-29 |
CA2724550C (en) | 2017-01-03 |
WO2009143454A3 (en) | 2010-03-04 |
EP2296645A4 (en) | 2012-03-07 |
EP2296645A2 (en) | 2011-03-23 |
WO2009143454A2 (en) | 2009-11-26 |
EP2859916A3 (en) | 2015-04-29 |
US9198893B2 (en) | 2015-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2530462T3 (es) | Combinación terapia antitumoral | |
HK1139863A1 (en) | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha | |
GT201300320A (es) | Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer. | |
MY150797A (en) | Combination therapies comprising quinaxoline inhibitors of pi3k-alpha for use in the treatment of cancer | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
BR112015012295A2 (pt) | métodos para tratar um paciente, e, kit para identificar um paciente com câncer | |
HN2011000193A (es) | Derivados de piridazina como inhibidores de smo | |
CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
BR112012020311A2 (pt) | "compostos, medicamento, método para inibir um ciclo de divisão celular, método para a profilaxia ou tratamento de câncer, e, uso do composto." | |
TR201900306T4 (tr) | Mek inhibitörlerini kullanma yöntemleri. | |
BR112015022047A2 (pt) | métodos para tratar câncer de bexiga | |
CL2011001811A1 (es) | Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico. | |
TN2010000208A1 (en) | Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents | |
AR092899A1 (es) | Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion | |
UY32987A (es) | Nuevo uso antitumoral de cabazitaxel | |
BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
EA201591987A1 (ru) | Лечение злокачественной опухоли дигидропиразинопиразинами | |
BRPI0810384B8 (pt) | terapia enzimática anticâncer | |
BRPI0915439B8 (pt) | composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição | |
BR112012022243A2 (pt) | terapias inibidoras de autografia baseadas em tioxantona para tratar câncer | |
BRPI0916540B8 (pt) | inibidores do canal de ânion de superficíe de plasmódio como agentes antimaláricos | |
MX2009006574A (es) | Tratamiento de cancer de pulmon. | |
MY176599A (en) | Treatment of prostate cancer with tor kinase inhibitors | |
MX2013006319A (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek. | |
BR112012027393A2 (pt) | composto da fórmula geral i, composição farmacêutica, uso de um composto e método de tratamento de qualquer mamífero, notadamente um humano, afetado por câncer |